Document Detail


Accumulation of tissue advanced glycation end products correlated with glucose exposure dose and associated with cardiovascular morbidity in patients on peritoneal dialysis.
MedLine Citation:
PMID:  22857897     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVES: Accumulation of tissue advanced glycation end products (AGEs) is a marker of cumulative glycemic and/or oxidative stress. Cutaneous AGEs levels measured by skin autofluorescence correlate well with cardiovascular outcomes in diabetes and hemodialysis (HD) patients. The present study aimed to compare tissue AGEs levels with peritoneal dialysis (PD) and HD patients and to evaluate the relationship between skin autofluorescence and cardiovascular morbidity in patients on PD. METHODS: A total of 2388 maintenance dialysis patients (613 PD and 1775 HD) were enrolled in this cross-sectional study. Skin autofluorescence was measured non-invasively with an autofluorescence reader. Cardiovascular morbidity was defined as clinically diagnosed ischemic heart disease, heart failure, stroke or peripheral vascular disease from initiation of dialysis. RESULTS: More than 90% of patients on both PD and HD had met current dialysis adequacy targets. Compared to HD group, PD patients receiving conventional glucose-containing dialyzate had significantly higher skin autofluorescence values in each category of age and dialysis duration, irrespective of the presence or absence of diabetes. In PD patients, skin autofluorescence values were strongly correlated with the duration of PD and glucose exposure dose and independently associated with cardiovascular morbidity. Multivariate analysis revealed that glucose exposure dose and skin autofluorescence were the strongest risk factors for cardiovascular morbidity in PD patients after adjustment by age, gender, and other classic- or uremic-related risk factors. CONCLUSIONS: Accumulation of tissue AGEs provides a potential link between PD exposure of metabolic stress and progression of cardiovascular disease in patients on PD.
Authors:
Jianping Jiang; Pingyan Chen; Jianghua Chen; Xueqing Yu; Di Xie; Changlin Mei; Fei Xiong; Wei Shi; Wei Zhou; Xusheng Liu; Shiren Sun; Ping Zhang; Xiao Yang; Yixiang Zhang; Yanmin Zhang; Xinling Liang; Zhimin Zhang; Qizhan Lin; Yan Yu; Toshio Miyata; Jianwei Tian; Min Liang; Weihong Luo; Xin Xu; Fanfan Hou
Related Documents :
12111177 - Diverse patterns of acid-base abnormalities associated with a modified sigmoid neobladder.
21484307 - Comparison of radiological indices (sasss, m-sasss, basri-s, basri-t) in patients with ...
16691027 - Nephrotoxicity due to combination antibiotic therapy with vancomycin and aminoglycoside...
21960047 - Evaluation of skin thickness lesions in patients with lyme disease measured by modified...
2129827 - Characterization of peripheral blood lymphocytes in patients with non-cirrhotic portal ...
6785967 - Urinary granulopoietic activity in chronic myelogenous leukemia: follow-up and correlat...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-7-13
Journal Detail:
Title:  Atherosclerosis     Volume:  -     ISSN:  1879-1484     ISO Abbreviation:  Atherosclerosis     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-8-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0242543     Medline TA:  Atherosclerosis     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Affiliation:
Division of Nephrology, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Age-related increase of stem marker expression influences vascular smooth muscle cell properties.
Next Document:  Inhibition of neointimal hyperplasia in the rat carotid artery injury model by a HMGB1 inhibitor.